Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation. Background: Next-generation sequencing has identified somatic mutations that are prognostic of cancer. Patients and Methods: We evaluated the incidence and prognostic significance of somatic mutations in 89 myelodysplastic syndrome (MDS) patients who received an allogeneic hematopoietic cell transplantation. Next-generation sequencing was performed on paraffin embedded bone marrow, which was obtained at a median of 31 days before initiating the preparative regimen. Results: The 3 most common subtypes of MDS were refractory anemia with excess blasts (RAEB)-1 (35%), RAEB-2 (29%), and refractory cytopenia with multilineage dysplasia (18%). Most patients (91%) received a myeloablative regimen of fludarabine with intravenous busulfan. Somatic mutations (> 0) were identified in 39 (44%) of analyzed samples. The 6 most commonly identified gene mutations were ASXL1 (8%), DNMT3A (8%), RUNX1 (7%), KRAS (6%), IDH2 (4%), and TP53 (4%). The low incidence of mutations in our study sample might be explained by tissue source and stringent variant-calling methodology. Moreover, we speculate that the low incidence of mutations might, perhaps, also be explained by previous azacitidine treatment in 82% of cases. Multivariate analysis identified TP53 (hazard ratio [HR], 3.82; 95% confidence interval [CI], 1.12-13.09; P ¼ .03) and IDH2 mutations (HR, 4.74; 95% CI, 1.33-16.91; P ¼ .02) as predictors of inferior 3-year overall survival. Conclusion: This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre-or post-transplant therapy.
Introduction
Despite growing understanding of the genetic and molecular basis of myelodysplastic syndrome (MDS) as well as availability of epigenetic therapy, the disease remains incurable unless eligible patients are offered an allogeneic hematopoietic cell transplantation (allo-HCT). [1] [2] [3] [4] [5] [6] Nevertheless, only approximately half of the patients who undergo the procedure achieve durable remissions. 5, 6 Significant morbidity and mortality occurs despite efforts to optimize patient selection using disease-specific hematopoietic cell transplantation comorbidity indices. 7, 8 No randomized data exist for comparisons of allo-HCT versus nontransplant therapies in patients with MDS. Presently, the decision to offer an allo-HCT is on the basis of published decision models that have shown a significant benefit favoring an allo-HCT earlier in the disease course, for patients with intermediate-or higher-risk MDS whether allografted from histocompatible siblings or unrelated donors. 9, 10 Published retrospective single-institution or registry studies have also supported the benefit of an allo-HCT to eligible patients with MDS. [11] [12] [13] [14] Various clinical models have been developed aimed at improving outcomes in patients who undergo an allo-HCT for MDS by identifying patient's comorbidities 7, 15 and clinical characteristics of the disease. 16 These models, however, are unable to predict outcomes in individual cases. Availability of next-generation sequencing (NGS) has helped identify somatic mutations capable of prognosticating outcomes of patients with MDS and acute myeloid leukemia (AML). 1, 17, 18 Bejar et al evaluated, retrospectively, 87 subjects who underwent an allo-HCT for MDS, median age 58 (range, 19-73) years, and identified the presence of at least 1 somatic mutations in 80 of 87 (92%) of cases. 19 In their series, mutated ASXL1 was the most frequently observed mutation (n ¼ 25/87, 29%). 19 Moreover, mutations in TP53, TET2, and DNMT3A were associated with an inferior overall survival (OS) after allo-HCT; and presence of mutated TP53 was described as the most significant predictor of mortality after transplantation with a short median survival of 4.6 months. 19 This study highlights the importance of identifying strong predictors of adverse outcomes in patients with MDS who undergo allo-HCT to develop therapeutic strategies aimed at improving outcomes. 19 Integrating NGS as a prognostic tool represents a step in the right direction aimed at moving MDS therapeutics to a more personalized approach.
Patients and Methods

Patient and Treatment Characteristics
Patients were considered eligible for inclusion in this study if they were ! 18 years of age, received an allo-HCT for MDS between January 2005 and June 2012, and had available formalin-fixed paraffin embedded (FFPE) bone marrow (BM) samples from the pretransplant workup, which was performed within approximately 30 days from initiation of the preparative regimen. All samples were collected according to a protocol approved by the institutional review board of the University of South Florida. This study was conducted in accordance with the Declaration of Helsinki.
There were no limitations pertaining to use of a particular cell source (BM or granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells [PBSC] or cord blood), donor source (related or unrelated), or human leukocyte antigen (HLA)-matching status. HLA-matching was defined as 8 of 8 (class I: A, B, C; class II: DRB1). Moreover, there were no restrictions relating to the intensity of the preparative regimen used, whether myeloablative conditioning (MAC) or reduced intensity conditioning, or to a particular regimen for prophylaxis against graft versus host disease (GVHD). Acute GVHD was graded according to 1994 consensus criteria 20 and chronic GVHD using the National
Institutes of Health consensus development published in 2005. 21 Methods for DNA Sequencing and Mutational Analysis DNA was isolated from three 20-mm FFPE sections using the Qiagen DNA isolation kit (Hilden, Germany) supplemented with uracil-DNA glycosylase (UDG) to remove sections of nucleotides with FFPE-related artifacts. Subsequently, 100 ng of DNA was used to generate NGS libraries that were amplicon enriched for all coding regions of: ASXL1, TET2, SETBP1, IDH1, IDH2, EZH2, DNMT3A, TP53, SRSF2, U2AF1, ZRSF2, SF3B1, FLT3, NRAS, KRAS, CBL, KIT, JAK2, MPL, ABL1, RUNX1, ETV6, WT1, CEBPA, MLL, and NPM1. Bar coding and pooled samples were sequenced on the Illumina platform (San Diego, CA) with an average read depth of Â1500. The Qiagen GeneRead software suite was used for alignment and variant calling. Frameshift, nonsense, and missense variants that were not present in germline databases (Exome Variant Server and 1000 Genomes Project) at > 1% frequency and those that were predicted to be functionally significant using sorting intolerant from tolerant and Polyphen were deemed true mutations. The cutoff for variant allele frequency (VAF) was set at 10% to differentiate from FFPE artifact.
Statistical Methods
The baseline patient characteristics were summarized using descriptive statistics including median, SD, and range for continuous measures and proportions and frequencies for categorical measures. Probabilities of 3-year progression-free survival (PFS) and OS were calculated from the date of stem cell infusion using the KaplaneMeier method and the difference for various independent categorical variables was assessed using the log rank test. Statistical significance was set at < .05 for all comparisons. Multivariate analysis for PFS and OS was performed using the Cox proportional hazards regression model. The final multivariable model was selected by allowing variables with P < .1 to remain in the model and adjusting for percentage of BM myeloblasts, presence of > 0 mutation, and Revised International Prognostic Scoring System for Myelodysplastic Syndrome (R-IPSS). Cumulative incidences of acute and chronic GVHD, relapse/progression (CIR/P), and nonrelapse mortality (NRM) were generated and compared using the method of Gray. A 2-sided P value of < .05 was the defined cutoff for statistical significance. Statistical analysis was performed using SPSS version 22 (IBM Corp, Armonk, NY).
Results
Patient, Disease, and Transplant-Related Characteristics
Initially, we identified 139 patients who received an allo-HCT during the specified time period. However, 38 were excluded for inability to isolate DNA because of poor quality of FFPE BM samples and 12 because of diagnoses other than MDS (AML ¼ 4, chronic myelomonocytic leukemia ¼ 8). Accordingly, 89 patients
Mutations Associated With Inferior Survival After Allo-HCT (male ¼ 52%), median age 58 (range, 22-74) years, were included in this cohort. The 3 most common MDS types at the time of diagnosis, defined according to the 2008 World Health Organization criteria, were refractory anemia with excess blasts (RAEB)-1 (35%), RAEB-2 (29%), and refractory cytopenia with multilineage dysplasia (18%; Table 1) . A large proportion of the patients had received azacitidine before allo-HCT (82%) and 26% of them had achieved at least a partial response (PR; complete remission
At the time of allo-HCT, more than one-half of the cases (51%) had intermediate-, high-, or very high-risk disease according to the R-IPSS. Most patients received G-CSF mobilized PBSC (96%) mostly from unrelated donors (matched unrelated donors ¼ 48%, mismatched unrelated donors ¼ 15%, cord blood ¼ 3%; Table 1 ). The largest portion of patients (n ¼ 93; 92%) received a MAC regimen consisting of fludarabine with intravenous busulfan; and the cumulative busulfan area under the curve ranged from 3500 to
and 7500 [n ¼ 3]). Tacrolimus with methotrexate was the most commonly used regimen for GVHD prophylaxis (64%). These and other patient-, donor-, and disease-related characteristics are summarized in Table 1 .
Mutational Analysis
Incidence. Bone marrow samples for mutational analysis were obtained within a median of 31 (range, 9-76) days before initiation of the preparative regimen. Somatic mutations (> 0) at the time of allo-HCT were identified in 39 (44%) of analyzed BM samples. The most common mutations in decreasing order frequency were: ASXL1 (8%), DNMT3A (8%), RUNX1 (7%), KRAS (6%), IDH2 (4%), TP53 (4%), SRSF2 (3%), SF3B1 (3%), EZH2 (3%), TET2 (2%), WT1 (2%), CBL (1%), MLL (1%), MPL (1%), KIT (1%), ZRSF2 (1%), and U2AF1 (1%). There was no significant correlation between age and presence of > 0 mutation (age younger than 60 years ¼ 37% vs. age ! 60 ¼ 45%; Spearman correlation P ¼ .88).
Survival. The median follow-up for surviving patients was 49 (range, 12-100) months. The median survival for all patients was 29 months. Patients who harbored a TP53 or IDH2 mutations had median survivals of 6.1 months and 8.4 months, respectively. Three-Year OS. The 3-year OS for all patients was 49% (95% CI, 39%-59%). No difference in 3-year OS was observed between older (! 60 years; 52% [95% CI, 36%-68%]) versus younger patients (47%; 95% CI, 33%-61%; P ¼ .60). Moreover, patients harboring mutated TP53 or IDH2 had statistically significant inferior 3-year OS (TP53 mutated ¼ 0 vs. wild type ¼ 51%; 95% CI, 41%-62%; P ¼ .04); 3-year OS (IDH2 mutated ¼ 0 vs. 51% [95% CI, 41%-62%]; P ¼ .04; Figures 1 and 2) .
Three-year OS was not affected by presence of > 0 mutation (> 0 ¼ 51%; 95% CI, 35%-66%) versus no mutation (48%; 95% CI, 34%-62%; P ¼ .76; Figure 3 ), R-IPSS category ! high (high/very high ¼ 48%; 95% CI, 33%-64%) versus very low/low/intermediate (53%; 95% CI, 38%-67%; P ¼ .68), or presence of ! 5% myeloblasts in pretransplant BM (! 5% ¼ 48%; 95% CI, 31%-65% vs. < 5% ¼ 50%; 95% CI, 37%-62%; P ¼ .89).
Multivariate Analysis
Multivariate analysis identified the presence of IDH2 mutations as predictors of inferior 3-year PFS and OS. Presence of TP53 mutation predicted for inferior 3-year OS but not 3-year PFS (Table 2) .
Relapse/Progression. The CIR/P for all patients was 26% (95% CI, 18%-37%) at 1 year and 47% (95% CI, 38%-60%) at 3 years. The 3-year CIR/P was significantly higher in patients ! 60 years of age (66% [95% CI, 51%-85%] vs. 34% [95% CI, 23%-51%]; P ¼ .0002).
Acute and Chronic GVHD and NRM. The cumulative incidences of acute GVHD Grades II to IV and Grades III to IV by day 100 for the entire cohort were 80% (95% CI, 72%-89%) and 20% (95% CI, 13%-31%), respectively. The 1-year and 3-year Mutations Associated With Inferior Survival After Allo-HCT cumulative incidence of moderate or severe chronic GVHD for the entire cohort were 47% (95% CI, 38%-59%) and 54% (95% CI, 44%-65%), respectively. The 100-day, 1-year, and 3-year cumulative incidence of NRM for the entire cohort were 7% (95% CI, 3%-15%), 19% (95% CI, 12%-29%), and 28% (95% CI, 20%-39%), respectively.
Discussion
The presence of mutated TP53 is associated with an inferior OS and a strong trend for worse PFS in patients with MDS who undergo an allo-HCT (Table 2 ). In our study, the median survival of patients harboring TP53 mutations was only 6.1 months and the 3-year PFS and OS were 0. Lindsley et al showed that TP53 mutations are associated with shorter survival and a shorter time to relapse. 22 These findings are comparable with a previous single-institution study that reported a median survival of 4.6 months in mutated TP53 MDS. 19 In contrast to Bejar et al, who
reported an incidence of mutated TP53 of 21%, 19 in ours it was only 4%. Our study identified a relatively low frequency of mutations (> 0; 44% vs. 92% in Bejar et al 19 vs. 82% in Heuser et al 23 ). This difference could, in part, be explained by tissue source and variant-calling methodology, among others. First, in our study we sequenced 26 genes compared with 40 genes in Bejar et al. 19 Second, despite improvement in deamination mutations secondary to FFPE UDG treatment, more stringent variant-calling criteria were required to confidently differentiate true mutations from FFPE artifact. These include a VAF threshold of 10% and the addition of in silico functional variant analysis. There are other clinical reasons to explain the low incidence of mutated TP53 in our study vis à vis Behar et al. 19 For example, in our study only 27% had poor (25%) or very poor (2%) cytogenetic risk according to R-IPSS. In contrast, in Bejar et al 49% of patients had either À7/7q or þ1 (AE other; 17%) or a complex karyotype (32%). 19 Svobodova et al showed a strong association between mutated TP53 and complex karyotype. 24 Similarly, Kulasekararaj et al reported TP53 mutations in 72% of MDS with complex karyotype and existing 5q abnormalities. 25 In our population, 82% had been previously treated with azacitidine, which leads us to speculate whether hypomethylating agents might, perhaps, affect the incidence of such mutations. In our analysis we also identified IDH2 mutation as a predictor of poor post-transplant outcomes. Patients harboring mutated IDH2 had a median survival of only 8.4 months and a 3-year PFS and OS of 0. Heuser et al, using Illumina high-throughput sequencing in 308 patients (MDS ¼ 47%; secondary AML from MDS ¼ 53%) who received an allo-HCT reported an incidence of mutated IDH2 of 4.2%. 23 Mutated IDH2 was a prognostic predictor for high risk of relapse and inferior post-transplant survival. 23 Although mutations in ASXL1 occurred within the highest incidence (n ¼ 7.8%) in our study sample, its presence did not affect adversely post-transplant OS (hazard ratio, 0.90 [95% CI, 0.32-2.51]; P ¼ .84). Intriguingly, previous studies have shown inferior OS for patients with mutated ASXL1 in the nontransplant setting. 1, 26 It is plausible that allo-HCT overcomes the adverse effect of mutated ASXL1; however, large randomized controlled studies that compare an allo-HCT (or not) in patients with mutated ASXL1 MDS would be necessary to answer this question. We did not identify a correlation between presence of mutations (> 0) and older age (empirically defined as ! 60 years). Presence of 27 Fifty-two (41%) achieved an objective response (CR ¼ 18%). 27 It is very likely that therapies such as AG-221 or other genetically-driven treatments will be studied in the setting of early post-transplant consolidation and maintenance provided that they have acceptable toxicity. Moreover, novel approaches are required to effectively target mutated TP53.
Conclusion
Rapidly expanding knowledge pertaining to the prognostic significance of various gene mutations has only begun to augment disease risk prognostication for MDS. This study furthers the implementation of clinical genomics in this disease and will help incorporate novel therapies, for example IDH2 inhibitors or others, in the post-transplant setting aimed at reducing the risk associated with these mutations.
Clinical Practice Points
The findings of this study show that mutations in TP53 or IDH2 confer a poor prognosis in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Developing clinical trials to evaluate future strategies which include novel therapies in the peri-and/or post-transplant setting are necessary to improve outcomes of patients harboring these mutations.
